We are excited to announce that we received a Notice of Allowance from the United States Patent and Trademark Office for a patent that uses a personalized medicine approach to match genetic markers for chronic pain with therapeutic drugs, including the cannabis-derived compound cannabidiol.
Primary hyperparathyroidism is a disorder of the parathyroid glands caused by overproduction of parathyroid hormone (PTH). This overproduction leads to high blood calcium and causes symptoms such as muscle weakness, fatigue, depression, bone and joint pain, nausea, vomiting, constipation, confusion or impaired thinking and memory, kidney stones, frequent urination, and osteoporosis.
We are happy to announce that we have added 17 new gene panels to our Spotlight line of tests. These new tests will expand our menu by 65%, offering new testing options in neurology, endocrinology, epilepsy, developmental delay, mitochondrial disease, and other disease areas.
Autism spectrum disorder (ASD) and intellectual disability (ID) have long been considered clinically distinct conditions, but a closer look suggests the two may be linked and share an underlying genetic cause.
At Courtagen, we offer DNA testing that uses next generation sequencing to diagnose neurological, mitochondrial, and other disorders. Because the brain and mitochondria are so complex, many of our panels have a thousand genes or more.
After performing diagnostic testing on several thousand patients with seizure disorders, Courtagen's Clinical Team has described a variant in the ALG13 gene that directly causes infantile spasms, intellectual disability, and severe neurologic disease.
Earlier this week, voters in four states (Arkansas, Florida, Montana, and North Dakota) approved legislation that made medicinal marijuana legal in their respective states. Now more than half the states have approved medical marijuana in some form. It’s fitting that this landmark was reached in the month of November, which happens to be Epilepsy Awareness month.